RC48-ADC

Disitamab Vedotin · Jiangsu Hengrui Medicine Co., Ltd.

Drug timelines are a Plus or Pro feature.

30 regulatory and trial events tracked for RC48-ADC, covering 2019-08-21 to 2025-12-19. Get the full timeline:

Most recent: Clinical Trial Update: A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer [Phase 2]

See pricing